España
Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
10.647 / 17.032
#85169

Re: Farmas USA

Top 10
framus_morrigan

arggg prediccion, odio ese palabro. suena a cosas de pitonisos :)

por tecnico la rotura del soporte del canal daba una proyeccion de otro canal por debajo, con un potencial minimo de unos 30$ si la cosa se precipitaba a toda prisa.

Pero visto el mvto de estos dias en el que se ha arrepentido de dicha ruptura ... en estos momentos esa proyeccion a la baja queda anulada.

De todos modos aun tiene dos retos importantes, la superacion de la MM50 en 48,9 que ayer sirvio de freno dejando una vela umm que no invita al optimismo ( ya se vera ... ), y la MM20 en los 50,66. Hasta que no sean superadas esta pajara no va a ninguna parte.

BLUE

 

edito: mirando el grafico semanal

tiene muchos obstaculos por arriba, me sorprenderia que no tratara de apoyarse en la zona de 39-40$ de nuevo

 

 

http://www.rankia.com/foros/bolsa/respuestas/2437438-hemeroteca-biblioteca-farma

#85170

Re: Farmas USA

Top 10
framus_morrigan

VALEANT, buen mamporro post-earnings, -20% en pre

 

Valeant misses on EPS, cuts outlook, shares drop to $58

 

Valeant's (NYSE:VRX) EPS came in lower than expected, while revenue beat estimates. We covered that here.

Looking ahead, the picture isn't pretty. Valeant sees Q1 EPS of $1.30-1.55, vs. prior guidance of $2.35-2.55, and Street consensus of $2.63. Sees Q1 revenue of $2.3-2.4B vs. prior guidance of $2.8-3.1B and consensus of $2.8B.

Valeant sees full-year EPS of $9.50-10.50 vs. prior guidance of $13.25-$13.75 and consensus of $13.24. Sees full-year revenue of $11-$11.2B vs. prior guidance of $12.5-12.7B and consensus of $12.4B.

CEO Michael Pearson: "The challenges of the past few months are not yet behind us and our goal for 2016 is to better balance our priorities across all of our constituencies - physicians, patients, employees, payors, debt holders and shareholders. I want to again thank all our dedicated employees, as well as the entire management team, for their diligence throughout this difficult time to ensure that the business remains solid.

"In discussion with the Board, we have assumed lower growth in our U.S. dermatology, gastrointestinal, and woman's health portfolios, as well as certain geographies like Western Europe, while keeping our expenses largely unchanged. We plan to work hard to improve these metrics by delivering higher revenues and reducing our costs and, if successful, we hope to beat this guidance in the quarters to come. In the meantime, we are comfortable with our current liquidity position and cash flow generation for the rest of the year, and remain well positioned to meet our obligations."

 

http://www.rankia.com/foros/bolsa/respuestas/2437438-hemeroteca-biblioteca-farma

#85174

Re: Farmas USA

si, pero con un fármaco que funciona en leucemia, te sube un 400% de la noche a la mañana. bien por ellos!
yo no los conocía, fuera de radar completamente...

#85175

Re: Farmas USA

Celator, la había tenido en cartera...

CPXX

#85176

Re: Farmas USA

Top 25
anaramos

Entre los titulares d hoy:

The average price of branded prescription drugs in the U.S. has doubled in the past five years, a finding that threatens to fuel the political backlash against high prices. Express Scripts (NASDAQ:ESRX), the country's largest pharmacy group, said the average wholesale price of branded medicines (which are protected by patents) rose 16% last year and was up a total of 98% since 2011. High drug costs have become a persistent theme in the current U.S. election campaigns, with both the Democratic and Republican frontrunners, Hillary Clinton and Donald Trump, pledging to crack down on elevated prices.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

Te puede interesar...
  1. Ciao $COIN. Comunicado de venta de Coinbase
  2. La mejor inversión: la formación
  3. La esclavitud de Musk
  4. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?
  5. Kyndryl (KD)
  1. La mejor inversión: la formación
  2. Ciao $COIN. Comunicado de venta de Coinbase
  3. Barrick Gold ¿Oportunidad?
  4. La esclavitud de Musk
  5. Inflación y tipos en el punto de mira, la historia no se repite pero rima